Analysis of prognostic factors on trifluridine-tipiracil plus bevacizumab treatment in metastatic colorectal cancer: A retrospective real-world analysis

被引：0
|
作者：
Onishi, M. [1 ]
Hirose, T. [1 ]
Shoji, H. [1 ]
Okita, N. T. [1 ]
Hirano, H. [1 ]
Takashima, A. [1 ]
Kato, K. [1 ]
机构：
[1] NCCH Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Tsukiji Campus,Chuo Ku, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
99P
引用
收藏
页码：S1441 / S1441
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment
    Signorelli, C.
    Schirripa, M.
    Chilelli, M. G.
    Calegari, M. A.
    Basso, M.
    Anghelone, A.
    Lucchetti, J.
    Minelli, A.
    Angotti, L.
    Morelli, C.
    Dell'Aquila, E.
    Cosimati, A.
    Gemma, D.
    Ribelli, M.
    Corsi, D. C.
    Arrivi, G.
    Zoratto, F.
    Morandi, M. G.
    Santamaria, F.
    Saltarelli, R.
    Ruggeri, E. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S719 - S719
  • [42] A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States
    Nevala-Plagemann, Christopher
    Sama, Shashank
    Ying, Jian
    Shen, Jincheng
    Haaland, Benjamin
    Florou, Vaia
    Garrido-Laguna, Ignacio
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (03): : 257 - 264
  • [43] Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Cheung, W. Y.
    Kavan, P.
    Dolley, A.
    CURRENT ONCOLOGY, 2020, 27 (05) : E451 - E458
  • [44] Trifluridine-tipiracil (FTD/TPI) plus bevacizumab (BV) in patients (pts) with pretreated metastatic colorectal cancer (mCRC): A real-life Italian multicenter experience
    Trovato, G.
    Carullo, M.
    Zoratto, F.
    Tamberi, S.
    Bergamo, F.
    Basso, M.
    Calegari, M. A.
    Puccini, A.
    Pastorino, A.
    Schirripa, M.
    Lucchetti, J.
    Arrivi, G.
    Morelli, C.
    Cerma, K.
    Troiani, T.
    Morano, F.
    Cremolini, C.
    Martinelli, E.
    Tortora, G.
    Salvatore, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S45 - S45
  • [45] Real-world analysis of patient characteristics and outcomes among patients with metastatic colorectal cancer receiving trifluridine/tipiracil (FTD/TPI) plus bevacizumab versus FTD/TPI monotherapy.
    Hubbard, Joleen M.
    Lee, Lulu K.
    Grisolano, Jay L.
    Perkowski, Kacper
    Salimi, Tehseen
    Kazerooni, Reza
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 34 - 34
  • [46] Exploratory analysis of trifluridine/tipiracil in late-stage metastatic colorectal cancer (mCRC): Prognostic factors
    Karthaus, Meinolf
    Hoell, B.
    Zaun, G.
    Guyot, M.
    Schuler, Martin H.
    Kasper, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis
    Signorelli, Carlo
    Chilelli, Mario Giovanni
    Giannarelli, Diana
    Basso, Michele
    Calegari, Maria Alessandra
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Zurlo, Ina Valeria
    Schirripa, Marta
    Morelli, Cristina
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Gemma, Donatello
    Ribelli, Marta
    Emiliani, Alessandra
    Corsi, Domenico Cristiano
    Arrivi, Giulia
    Mazzuca, Federica
    Zoratto, Federica
    Morandi, Maria Grazia
    Santamaria, Fiorenza
    Saltarelli, Rosa
    Ruggeri, Enzo Maria
    CANCERS, 2023, 15 (24)
  • [48] Frequency and management of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice
    Lago, N. Martinez
    Rendo, C. Reboredo
    Chucla, T. Calleja
    Salvador, M. Mateos
    Fernandez, F. Busto
    Gomez, J. de la Camara
    Reboredo-Lopez, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S100 - S101
  • [49] Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
    Koper, Agnieszka
    Wilenski, Slawomir
    Sledzinska, Paulina
    Bebyn, Marek
    Koper, Krzysztof
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (12) : 10867 - 10877
  • [50] Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
    Signorelli, Carlo
    Calegari, Maria Alessandra
    Basso, Michele
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Zurlo, Ina Valeria
    Schirripa, Marta
    Chilelli, Mario Giovanni
    Morelli, Cristina
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Gemma, Donatello
    Ribelli, Marta
    Emiliani, Alessandra
    Corsi, Domenico Cristiano
    Arrivi, Giulia
    Mazzuca, Federica
    Zoratto, Federica
    Morandi, Maria Grazia
    Santamaria, Fiorenza
    Saltarelli, Rosa
    Ruggeri, Enzo Maria
    CURRENT ONCOLOGY, 2023, 30 (06) : 5456 - 5469
12345